Please Scroll Down to See Forums Below
Any way to know for sure if your growth plates are closed?
- Thread starter tommboy
- Start date
- Status
macrophage69alpha
New member
tommboy said:
varies. use an AI. and be careful with progestins.
if using an AI with EQ, TEST, dbol or the use of compounds like anavar, masteron and primo etc. There is little risk of premature closure
macrophage69alpha
New member
some IMHO frightening reading- reminiscent of nazi eugenics
Acta Endocrinol Suppl (Copenh). 1986;279:170-3. Links
Oestrogen treatment of adolescent tall girls; short term side effects.Trygstad O.
In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height greater than +2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactinoma was observed) or events happening by chance.
: Acta Clin Belg. 1993;48(1):11-9. Links
[Growth inhibition using estrogens in constitutionally tall girls][Article in Dutch]
Du Caju MV, Bleyaert S, Op De Beeck L.
Universitair Ziekenhuis Antwerpen.
Estrogen treatment in high doses is effective in reducing adult stature in constitutionally tall girls. In this study, growth data of 38 normal girls with a predicted final height beyond 178 cm, are reported. They were treated with ethinyloestradiol in a daily dose of 0.200 mg until the epiphyseal plates were practically fused. In addition, medroxyprogesterone acetate at a dose of 10 mg daily was given for 5 to 12 days every month. The reduction of final height occurred with decreased growth velocity and accelerated epiphyseal closure. The major factor affecting the response to treatment was skeletal age. The lower the skeletal age, the greater the difference between the predicted final height and the final height. This gain was directly related to the growth potential at start of therapy. The best time to start treatment might be the pre-menarche period at a bone age of 12 years. Serious side-effects were not reported, but treatment should be employed only when height prediction is excessive
and finally some reason
1: Eur J Pediatr. 1997 Dec;156(12):905-10. Links
Outcome in tall stature. Final height and psychological aspects in 220 patients with and without treatment.Binder G, Grauer ML, Wehner AV, Wehner F, Ranke MB.
In 135 women and 85 men who initially presented for tall stature, the outcome in treated (56 women and 33 men; cases) and untreated (controls) was investigated. At the time of height prediction, cases were significantly taller (P < or = 0.03) than the controls, they had higher target heights (P < 0.001) and adult height predictions (P < 0.001) (according to Bailey and Pinneau) compared to the controls. Bone age (according to Greulich and Pyle) and chronological age were well matched in both groups. Final height was measured after cessation of growth at a mean age above 21.5 years. The final height prediction according to Bailey and Pinneau (BP method) overestimated the final height in controls. The mean error of estimation was -0.14 cm (+/- 3.10) in women, and -1.86 cm (+/- 4.37) in men. Age at the time of prediction did not significantly correlate with the degree of the prediction error. Sex hormone therapy comprised a daily oral dose of 7.5 mg conjugated oestrogens in girls (plus 5 mg dydrogesterone for 10 days a month), while boys received 500 mg testosterone enantate, intramuscularly, every 2 weeks. Therapy was well tolerated. The mean corrected effect of height reducing therapy was 3.6 cm (range: 11.9 cm to -3.3 cm) in women and 4.4 cm (range: 14.2 cm to -5.2 cm) in men. Therapy was significantly more effective when started at an earlier chronological (P < 0.01) and bone age (P < 0.01). The residual mean growth, after therapy was stopped, was 1.8 (+/- 1.6) cm in women and 3.1 (+/- 2.3) cm in men. In men, post-treatment growth was inversely correlated to chronological age (P < 0.01) and bone age (P < 0.05) at the end of treatment, while these correlations were not significant in women. Both groups had a higher educational level than the normal population. Treated tall women reported teasing because of tallness more frequently than controls. In tall men, practical issues such as clothing size predominated. Maximum tolerated height in males was 200 cm and in females 180 cm, thus being nearly analogous to the actual professional criteria for treatment recommendation. A positive attitude to treatment was documented in over 90% of treated individuals. CONCLUSIONS: Our results show that the BP method gives acceptable adult height predictions in girls, but less accurate predictions in boys. The treatment with high doses of sex hormones was low effective in both sexes and showed a wide range of response. For success, treatment must be initiated in early puberty and terminated late. The answers to a questionnaire revealed no major psychological or social maladjustment of treated individuals compared to those untreated.
Acta Endocrinol Suppl (Copenh). 1986;279:170-3. Links
Oestrogen treatment of adolescent tall girls; short term side effects.Trygstad O.
In 1980-1985 680 preadolescent tall girls were treated with pharmacological doses of oestrogen to reduce final height. Indications for the therapy were predicted final height greater than +2.5 SD (180.75 cm), idiopathic scoliosis, and psychosocial problems. Until 1976 141 girls were given diethyl stilboestrol 5 mg daily. By advice of Prader this was then replaced by ethinyl oestradiol and a progestin was given on days 5-10 each month. The mean duration of therapy was close to 2 years. The observed short-term unwanted effects were due to the pharmacological actions of the drugs, (11 girls had galactorrhoea at the end of therapy; no pituitary prolactinoma was observed) or events happening by chance.
: Acta Clin Belg. 1993;48(1):11-9. Links
[Growth inhibition using estrogens in constitutionally tall girls][Article in Dutch]
Du Caju MV, Bleyaert S, Op De Beeck L.
Universitair Ziekenhuis Antwerpen.
Estrogen treatment in high doses is effective in reducing adult stature in constitutionally tall girls. In this study, growth data of 38 normal girls with a predicted final height beyond 178 cm, are reported. They were treated with ethinyloestradiol in a daily dose of 0.200 mg until the epiphyseal plates were practically fused. In addition, medroxyprogesterone acetate at a dose of 10 mg daily was given for 5 to 12 days every month. The reduction of final height occurred with decreased growth velocity and accelerated epiphyseal closure. The major factor affecting the response to treatment was skeletal age. The lower the skeletal age, the greater the difference between the predicted final height and the final height. This gain was directly related to the growth potential at start of therapy. The best time to start treatment might be the pre-menarche period at a bone age of 12 years. Serious side-effects were not reported, but treatment should be employed only when height prediction is excessive
and finally some reason
1: Eur J Pediatr. 1997 Dec;156(12):905-10. Links
Outcome in tall stature. Final height and psychological aspects in 220 patients with and without treatment.Binder G, Grauer ML, Wehner AV, Wehner F, Ranke MB.
In 135 women and 85 men who initially presented for tall stature, the outcome in treated (56 women and 33 men; cases) and untreated (controls) was investigated. At the time of height prediction, cases were significantly taller (P < or = 0.03) than the controls, they had higher target heights (P < 0.001) and adult height predictions (P < 0.001) (according to Bailey and Pinneau) compared to the controls. Bone age (according to Greulich and Pyle) and chronological age were well matched in both groups. Final height was measured after cessation of growth at a mean age above 21.5 years. The final height prediction according to Bailey and Pinneau (BP method) overestimated the final height in controls. The mean error of estimation was -0.14 cm (+/- 3.10) in women, and -1.86 cm (+/- 4.37) in men. Age at the time of prediction did not significantly correlate with the degree of the prediction error. Sex hormone therapy comprised a daily oral dose of 7.5 mg conjugated oestrogens in girls (plus 5 mg dydrogesterone for 10 days a month), while boys received 500 mg testosterone enantate, intramuscularly, every 2 weeks. Therapy was well tolerated. The mean corrected effect of height reducing therapy was 3.6 cm (range: 11.9 cm to -3.3 cm) in women and 4.4 cm (range: 14.2 cm to -5.2 cm) in men. Therapy was significantly more effective when started at an earlier chronological (P < 0.01) and bone age (P < 0.01). The residual mean growth, after therapy was stopped, was 1.8 (+/- 1.6) cm in women and 3.1 (+/- 2.3) cm in men. In men, post-treatment growth was inversely correlated to chronological age (P < 0.01) and bone age (P < 0.05) at the end of treatment, while these correlations were not significant in women. Both groups had a higher educational level than the normal population. Treated tall women reported teasing because of tallness more frequently than controls. In tall men, practical issues such as clothing size predominated. Maximum tolerated height in males was 200 cm and in females 180 cm, thus being nearly analogous to the actual professional criteria for treatment recommendation. A positive attitude to treatment was documented in over 90% of treated individuals. CONCLUSIONS: Our results show that the BP method gives acceptable adult height predictions in girls, but less accurate predictions in boys. The treatment with high doses of sex hormones was low effective in both sexes and showed a wide range of response. For success, treatment must be initiated in early puberty and terminated late. The answers to a questionnaire revealed no major psychological or social maladjustment of treated individuals compared to those untreated.
transform_me
New member
Hi,
Please see these two images (sorry for the bad quality )
1st image
img521.imageshack.us/img521/5166/98355423.jpg
2nd image
img718.imageshack.us/img718/1852/95112770.jpg
Now, what i want to know is just one answer (with reference or example to get me satisfied ) Is my growth plates closed or not?
this is my hip bone x-ray. So, please let me know if they are still open or closed.
Thanks in advance!
Please see these two images (sorry for the bad quality )
1st image
img521.imageshack.us/img521/5166/98355423.jpg
2nd image
img718.imageshack.us/img718/1852/95112770.jpg
Now, what i want to know is just one answer (with reference or example to get me satisfied ) Is my growth plates closed or not?
this is my hip bone x-ray. So, please let me know if they are still open or closed.
Thanks in advance!
RADAR
Well-known member
This thread is 5 yrs old and the images do not work ...make a new thread for your answer.
- Status
Similar threads
